167 related articles for article (PubMed ID: 19582472)
1. Is intravitreal bevacizumab treatment effective in diffuse diabetic macular edema?
Biester S; Ziemssen F; Ulrich Bartz-Schmidt K; Gelisken F
Graefes Arch Clin Exp Ophthalmol; 2009 Nov; 247(11):1575-7. PubMed ID: 19582472
[No Abstract] [Full Text] [Related]
2. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
3. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
4. The article by Kook et al 1 on the 1-year effect of bevacizumab in patients with chronic diffuse diabetic macular edema (DME).
Querques G
Retina; 2009 May; 29(5):718-9; author reply 719-20. PubMed ID: 19430285
[No Abstract] [Full Text] [Related]
5. Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study.
Bonini-Filho M; Costa RA; Calucci D; Jorge R; Melo LA; Scott IU
Am J Ophthalmol; 2009 Jun; 147(6):1022-30, 1030.e1-5. PubMed ID: 19327746
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up.
Arevalo JF; Sanchez JG; Fromow-Guerra J; Wu L; Berrocal MH; Farah ME; Cardillo J; Rodríguez FJ;
Graefes Arch Clin Exp Ophthalmol; 2009 Jun; 247(6):735-43. PubMed ID: 19189118
[TBL] [Abstract][Full Text] [Related]
7. OCT and cataract.
Falavarjani KG; Modarres M; Nikeghbali A
Ophthalmology; 2010 Apr; 117(4):849; author reply 849-50. PubMed ID: 20346827
[No Abstract] [Full Text] [Related]
8. Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema.
Chung EJ; Roh MI; Kwon OW; Koh HJ
Retina; 2008; 28(7):957-63. PubMed ID: 18698297
[TBL] [Abstract][Full Text] [Related]
9. Diffuse diabetic macular oedema treated with intravitreal bevacizumab or triamcinolone acetonide.
Rensch F; Spandau UH; Wickenhäuser A; Jonas JB
Acta Ophthalmol; 2010 Mar; 88(2):e36-7. PubMed ID: 19210330
[No Abstract] [Full Text] [Related]
10. Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema.
Chen E; Hsu J; Park CH
Ophthalmic Surg Lasers Imaging; 2009; 40(1):68-70. PubMed ID: 19205502
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery.
Takamura Y; Kubo E; Akagi Y
Ophthalmology; 2009 Jun; 116(6):1151-7. PubMed ID: 19376589
[TBL] [Abstract][Full Text] [Related]
12. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
Kumar V; Ghosh B; Raina UK; Goel N
Am J Ophthalmol; 2008 Dec; 146(6):974; author reply 974-5. PubMed ID: 19027427
[No Abstract] [Full Text] [Related]
13. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema.
Sheth S; Rush R; Natarajan S; Gillies M
Clin Exp Ophthalmol; 2011; 39(7):673-81. PubMed ID: 22452685
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes.
Yanyali A; Aytug B; Horozoglu F; Nohutcu AF
Am J Ophthalmol; 2007 Jul; 144(1):124-6. PubMed ID: 17601433
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal fasudil combined with bevacizumab for persistent diabetic macular edema: a novel treatment.
Ahmadieh H; Nourinia R; Hafezi-Moghadam A
JAMA Ophthalmol; 2013 Jul; 131(7):923-4. PubMed ID: 23640178
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema.
Kumar V; Ghosh B; Raina UK; Goel N
Acta Ophthalmol; 2010 Mar; 88(2):e3; author reply e4. PubMed ID: 19549100
[No Abstract] [Full Text] [Related]
17. Bevacizumab and macular edema.
Kumar A
Ophthalmology; 2008 Mar; 115(3):585. PubMed ID: 18319106
[No Abstract] [Full Text] [Related]
18. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.
Arevalo JF; Sanchez JG; Wu L; Maia M; Alezzandrini AA; Brito M; Bonafonte S; Lujan S; Diaz-Llopis M; Restrepo N; Rodríguez FJ; Udaondo-Mirete P;
Ophthalmology; 2009 Aug; 116(8):1488-97, 1497.e1. PubMed ID: 19545900
[TBL] [Abstract][Full Text] [Related]
19. Effect of intravitreal triamcinolone in diabetic macular edema unresponsive to intravitreal bevacizumab.
Jeon S; Lee WK
Retina; 2014 Aug; 34(8):1606-11. PubMed ID: 24553409
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema.
Soheilian M; Ramezani A; Obudi A; Bijanzadeh B; Salehipour M; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Peyman GA
Ophthalmology; 2009 Jun; 116(6):1142-50. PubMed ID: 19376585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
